当前位置: 首页 >> 检索结果
801. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.
作者: Sandro Ardizzone.;Giovanni Maconi.;Gianluca M Sampietro.;Antonio Russo.;Elisa Radice.;Elisabetta Colombo.;Venerina Imbesi.;Mirko Molteni.;Pier Giorgio Danelli.;Angelo M Taschieri.;Gabriele Bianchi Porro.
来源: Gastroenterology. 2004年127卷3期730-40页
Because the reoperation rate for Crohn's disease is high after resective surgery, use of conservative surgery has increased. Mesalamine was investigated for the prevention of postoperative relapse, with disappointing results. The role of azathioprine in the postoperative setting is unknown. We aimed to compare the efficacy and safety of azathioprine and mesalamine in the prevention of clinical and surgical relapse in patients who have undergone conservative surgery for Crohn's disease.
802. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
作者: Stephen B Hanauer.;Burton I Korelitz.;Paul Rutgeerts.;Mark A Peppercorn.;Ronald A Thisted.;Russell D Cohen.;Daniel H Present.
来源: Gastroenterology. 2004年127卷3期723-9页
No therapy has been shown to reliably prevent the evolution of postoperative recurrence of Crohn's disease. The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after resection and ileocolic anastomosis.
803. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis.
作者: Carlo Merkel.;Renato Marin.;Paolo Angeli.;Pierluigi Zanella.;Martina Felder.;Elisabetta Bernardinello.;Giorgio Cavallarin.;Massimo Bolognesi.;Carlo Donada.;Barbara Bellini.;Pierluigi Torboli.;Angelo Gatta.; .
来源: Gastroenterology. 2004年127卷2期476-84页
Beta-blockers are extensively used to prevent variceal bleeding in patients with large esophageal varices. It is not established if beta-blockers delay the growth of small varices.
804. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
作者: Loren Laine.;Eric S Maller.;Chang Yu.;Hui Quan.;Thomas Simon.
来源: Gastroenterology. 2004年127卷2期395-402页
We assessed the risk of ulcers with low-dose aspirin and the interaction of low-dose aspirin with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspirin, rofecoxib + low-dose aspirin, and ibuprofen.
805. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634].
作者: Pieter C J ter Borg.;Erik van Os.;Walter W van den Broek.;Bettina E Hansen.;Henk R van Buuren.
来源: BMC Gastroenterol. 2004年4卷13页
Fatigue is a major clinical problem in many patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined. Recently, a large proportion of patients with these diseases was found to have symptoms of depression. Because fatigue is a frequent symptom of depression and there is some evidence that treatment with an antidepressant improves fatigue in patients with fibromyalgia, we hypothesised that the antidepressant fluvoxamine might improve fatigue related to PBC and PSC.
806. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
作者: Patrizia Farci.;Tania Roskams.;Luchino Chessa.;Giovanna Peddis.;Anna Paola Mazzoleni.;Rosetta Scioscia.;Giancarlo Serra.;Maria Eliana Lai.;Maurizio Loy.;Luciano Caruso.;Valeer Desmet.;Robert H Purcell.;Angelo Balestrieri.
来源: Gastroenterology. 2004年126卷7期1740-9页
Little is known about the long-term effects of interferon alpha on clinical outcome and survival of patients with chronic hepatitis D.
807. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
作者: Nezam H Afdhal.;Douglas T Dieterich.;Paul J Pockros.;Eugene R Schiff.;Mitchell L Shiffman.;Mark S Sulkowski.;Teresa Wright.;Zobair Younossi.;Betty L Goon.;K Linda Tang.;Peter J Bowers.; .
来源: Gastroenterology. 2004年126卷5期1302-11页
Combination therapy with interferon alpha (IFN-alpha) and ribavirin (RBV) or pegylated IFN-alpha (PEG-IFN-alpha)/RBV for chronic hepatitis C virus (HCV) infection often causes anemia, prompting RBV dose reduction/discontinuation. This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients.
808. Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
作者: Michael Schultz.;Antje Timmer.;Hans H Herfarth.;R Balfour Sartor.;Jon A Vanderhoof.;Heiko C Rath.
来源: BMC Gastroenterol. 2004年4卷5页
Experimental studies have shown that luminal antigens are involved in chronic intestinal inflammatory disorders such as Crohn's disease and ulcerative colitis. Alteration of the intestinal microflora by antibiotic or probiotic therapy may induce and maintain remission. The aim of this randomized, placebo-controlled trial was to determine the effect of oral Lactobacillus GG (L. GG) to induce or maintain medically induced remission.
809. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
作者: Mitchell L Shiffman.;Adrian M Di Bisceglie.;Karen L Lindsay.;Chihiro Morishima.;Elizabeth C Wright.;Gregory T Everson.;Anna S Lok.;Timothy R Morgan.;Herbert L Bonkovsky.;William M Lee.;Jules L Dienstag.;Marc G Ghany.;Zachary D Goodman.;James E Everhart.; .
来源: Gastroenterology. 2004年126卷4期1015-23; discussion 947页
The most effective therapy currently available for treatment of chronic hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy.
810. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial.
作者: Rainer Isenmann.;Michael Rünzi.;Martina Kron.;Stefan Kahl.;Dietmar Kraus.;Norbert Jung.;Ludwig Maier.;Peter Malfertheiner.;Harald Goebell.;Hans G Beger.; .
来源: Gastroenterology. 2004年126卷4期997-1004页
Antibiotic prophylaxis in necrotizing pancreatitis remains controversial. Until now, there have been no double-blind studies dealing with this topic.
811. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
作者: Hiroaki Ito.;Masakazu Takazoe.;Yoshihiro Fukuda.;Toshifumi Hibi.;Kazuo Kusugami.;Akira Andoh.;Takayuki Matsumoto.;Takehira Yamamura.;Junichi Azuma.;Norihiro Nishimoto.;Kazuyuki Yoshizaki.;Takashi Shimoyama.;Tadamitsu Kishimoto.
来源: Gastroenterology. 2004年126卷4期989-96; discussion 947页
Interleukin-6 (IL-6) regulates immune response and inflammation. We carried out a pilot placebo-controlled study to investigate the efficacy, pharmacokinetics, and safety of MRA, a humanized monoclonal antibody to IL-6 receptor, in patients with active Crohn's disease.
812. Adenoma characteristics as risk factors for recurrence of advanced adenomas.
作者: M E Martínez.;R Sampliner.;J R Marshall.;A K Bhattacharyya.;M E Reid.;D S Alberts.
来源: Gastroenterology. 2001年120卷5期1077-83页
The link between adenoma characteristics at baseline colonoscopy and adenoma recurrence is poorly understood. We assessed whether the number, size, location, or histology of resected adenomas was related to the probability of recurrence of advanced lesions.
813. Effect of four-day psyllium supplementation on bowel preparation for colonoscopy:A prospective double blind randomized trial [ISRCTN76623768].
Patients with new onset constipation or presumed hemorrhoid bleeding frequently require the use of both fiber supplements and diagnostic colonoscopy. We sought to determine whether preliminary fiber supplementation would alter the tolerability or efficacy of a standard bowel preparation for colonoscopy
814. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.
作者: Carmen Zafra.;Juan G Abraldes.;Juan Turnes.;Annalisa Berzigotti.;Mercedes Fernández.;Juan C Garca-Pagán.;Juan Rodés.;Jaime Bosch.
来源: Gastroenterology. 2004年126卷3期749-55页
In cirrhosis, an insufficient release of nitric oxide contributes to increased hepatic resistance and portal pressure and enhances the postprandial increase in portal pressure. We hypothesized that simvastatin, which enhances Akt-dependent endothelial nitric oxide synthase phosphorylation, may increase hepatic nitric oxide release and decrease hepatic resistance in patients with cirrhosis and portal hypertension.
815. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor.
作者: Robert Paul Willert.;Clifford J Woolf.;Anthony Robert Hobson.;Claire Delaney.;David G Thompson.;Qasim Aziz.
来源: Gastroenterology. 2004年126卷3期683-92页
Visceral hypersensitivity is a common feature of functional gastrointestinal disorders. One speculated mechanism is an activity-dependent increase in spinal cord neuronal excitability (central sensitization), which is dependent on activation of the N-methyl-D-aspartate (NMDA) receptor. Our aims were to determine whether the development and maintenance of human visceral hypersensitivity is NMDA receptor mediated.
816. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study.
作者: Christophe Bureau.;Juan Carlos Garcia-Pagan.;Philippe Otal.;Gilles Pomier-Layrargues.;Valérie Chabbert.;Carlos Cortez.;Pierre Perreault.;Jean Marie Péron.;Juan G Abraldes.;Louis Bouchard.;José Ignacio Bilbao.;Jaume Bosch.;Hervé Rousseau.;Jean Pierre Vinel.
来源: Gastroenterology. 2004年126卷2期469-75页
A 50% dysfunction rate at 1 year is one of the main drawbacks of the transjugular intrahepatic portosystemic shunt procedure. Preliminary experimental and clinical studies suggest that the use of stents covered with polytetrafluoroethylene could tremendously decrease this risk.
817. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
作者: Francis M Giardiello.;Robert A Casero.;Stanley R Hamilton.;Linda M Hylind.;Jill D Trimbath.;Deborah E Geiman.;Katharine R Judge.;Walter Hubbard.;G Johan A Offerhaus.;Vincent W Yang.
来源: Gastroenterology. 2004年126卷2期425-31页
Familial adenomatous polyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by development of colorectal adenomas and, ultimately, colorectal cancer. The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemoprevention with the nonsteroidal anti-inflammatory drug sulindac was evaluated.
818. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
作者: Paul Rutgeerts.;Brian G Feagan.;Gary R Lichtenstein.;Lloyd F Mayer.;Stefan Schreiber.;Jean Frederic Colombel.;Daniel Rachmilewitz.;Douglas C Wolf.;Allan Olson.;Weihang Bao.;Stephen B Hanauer.
来源: Gastroenterology. 2004年126卷2期402-13页
This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice.
819. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
作者: George K K Lau.;Harry H Y Yiu.;Daniel Y T Fong.;Hoi-Ching Cheng.;Wing-Yan Au.;Lydia S F Lai.;Micheal Cheung.;Hai-Ying Zhang.;Albert Lie.;Roger Ngan.;Raymond Liang.
来源: Gastroenterology. 2003年125卷6期1742-9页
Hepatitis B virus reactivation is a serious cause of morbidity and mortality in hepatitis B surface antigen-positive patients treated with chemotherapy. We compared the efficacy of early and deferred preemptive lamivudine therapy in reducing the incidence of hepatitis due to hepatitis B virus reactivation in hepatitis B surface antigen-positive lymphoma patients treated with chemotherapy.
820. Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial.
作者: Ruel T Garcia.;John P Cello.;Mindie H Nguyen.;Stanley J Rogers.;Alex Rodas.;Huy N Trinh.;Neil H Stollman.;Gail Schlueck.;Kenneth R McQuaid.
来源: Gastroenterology. 2003年125卷6期1606-12页
In the United States, upper gastrointestinal endoscopy is usually performed using intravenous sedation. Sedation increases the rate of both complications and costs of endoscopy. Unsedated esophagogastroduodenoscopy (EGD) using conventional 8-11-mm endoscopes is an alternative to sedated endoscopy but is generally perceived as unacceptable to many American patients. Unsedated EGD using ultrathin 5-6-mm endoscopes is better tolerated. A randomized trial comparing unsedated ultrathin EGD (UT-EGD) with sedated conventional EGD (C-EGD) in a diverse American population is needed.
|